Oxbryta Given Promising Innovative Medicine Status in UK

Oxbryta Given Promising Innovative Medicine Status in UK

296742

Oxbryta Given Promising Innovative Medicine Status in UK

A Promising Innovative Medicine (PIM) designation has been granted to Oxbryta (voxelotor), a treatment to reduce the destruction of red blood cells in people, 12 and older, with sickle cell disease (SCD).  The designation, given to promising therapies that are likely to provide major benefit to patients, follows a review by the Medicines and Healthcare Products Regulatory Agency in the U.K. To receive this designation, products must seek to treat life-threatening or seriously debilitating medical…

You must be logged in to read/download the full post.